This is unpublished

Effie W.
Petersdorf
M.D.

she, her, hers
Physician & Research Faculty
Pinned
Academic
Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Madeline Dabney Adams Endowed Chair in AML Research
Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: Fred Hutch

Education, Training, Board Certifications 

  • M.D., McGill University, Canada
  • Residency, UW
  • Fellowship, UW
  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Clinical Expertise  

  • Hematopoietic stem cell transplantation
  • HLA typing
  • Acute Myelogenous Leukemia

Affiliations  

Publications

Research and/or clinical interests 

Dr. Effie Wang Petersdorf is an oncologist who studies how genetic factors influence the success of stem cell transplants. She pioneered molecular methods to compare differences between transplant donors and recipients in a key set of genes known as human leukocyte antigen, or HLA, genes. Mismatches in these genes, which play a central role in the immune response, raise the risk of graft-vs.-host disease (GVHD), a potentially life-threatening complication in which newly transplanted cells attack the patient’s body. Dr. Petersdorf has shown that precise and complete HLA typing, and matching of both donor and recipient, can make transplants safer. Transplants between imperfectly matched donors and recipients can also succeed, indicating that not all genetic differences have the same effects. Dr. Petersdorf spearheaded the formation of the International Histocompatibility Working Group, a worldwide collaboration among donor registries, transplant centers and HLA laboratories. She also looks beyond HLA typing to find new genes that may influence transplant success. She recently identified two new sites where DNA mismatches are important: a mismatch at one location increases GVHD risk, while a mismatch at the other enhances patient survival. Plans to offer typing of these new sites to future Hutch patients and donors are underway.